Form 4: TuHURA Biosciences CFO Acquires 489,848 Stock Options

TuHURA Biosciences' Chief Financial Officer, Dan Dearborn, acquired 489,848 stock options on November 12, 2024, which vest over three years.

Summary

• Dan Dearborn, the Chief Financial Officer of TuHURA Biosciences, acquired 489,848 stock options on November 12, 2024.
• The options have an exercise price of $4.94.
• The options become exercisable in three equal tranches on the first, second, and third anniversaries of November 12, 2024.
• The options expire on November 12, 2034.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns management with shareholder interests. There is no indication of any negative sentiment.

Positives

• The acquisition of stock options by the CFO could indicate confidence in the company's future performance.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a standard practice for executive compensation across the biotechnology sector.
• The vesting schedule of one-third per year over three years is a typical vesting structure.
• The exercise price of $4.94 is specific to TuHURA Biosciences and would need to be compared to similar companies to assess its relative value.

Stakeholder Impact

• The stock option grant could positively impact shareholder confidence by aligning management's interests with the company's long-term success.

Key Dates

Keywords

stock options, insider trading, executive compensation, TuHURA Biosciences, Dan Dearborn, CFO